Log in
NASDAQ:ORPH

Orphazyme A/S Stock Forecast, Price & News

$9.27
-0.23 (-2.42 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.20
Now: $9.27▼
$9.52
50-Day Range N/A
52-Week Range
$9.20
Now: $9.27▼
$11.07
Volume77,283 shs
Average Volume144,717 shs
Market Capitalization$321.31 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.70 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORPH
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.orphazyme.com
Phone45 39 17 82 72
Employees114

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares34,661,000
Market Cap$321.31 million
Next Earnings DateN/A
OptionableNot Optionable
$9.27
-0.23 (-2.42 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORPH News and Ratings via Email

Sign-up to receive the latest news and ratings for ORPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Orphazyme A/S (NASDAQ:ORPH) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Orphazyme A/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orphazyme A/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Orphazyme A/S.

What price target have analysts set for ORPH?

2 brokers have issued 12-month price objectives for Orphazyme A/S's stock. Their forecasts range from $13.00 to $27.00. On average, they expect Orphazyme A/S's stock price to reach $20.00 in the next year. This suggests a possible upside of 115.7% from the stock's current price.
View analysts' price targets for Orphazyme A/S.

Who are some of Orphazyme A/S's key competitors?

Some companies that are related to Orphazyme A/S include Stoke Therapeutics (STOK), Epizyme (EPZM), Amneal Pharmaceuticals (AMRX), Myovant Sciences (MYOV), Mersana Therapeutics (MRSN), Trillium Therapeutics (TRIL), Theravance Biopharma (TBPH), Generation Bio (GBIO), NGM Biopharmaceuticals (NGM), Zogenix (ZGNX), Phathom Pharmaceuticals (PHAT), Keros Therapeutics (KROS), Innoviva (INVA), Karyopharm Therapeutics (KPTI) and Cytokinetics (CYTK).
View all competitors.

Who are Orphazyme A/S's key executives?

Orphazyme A/S's management team includes the following people:
  • Ms. Kim Stratton, Chief Exec. Officer (Age 58)
  • Dr. Thomas Kirkegaard Jensen Ph.D., Co-Founder & Chief Scientific Officer (Age 43)
  • Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBA, Chief Financial Officer (Age 51)
  • Dr. Thomas Blaettler, Chief Medical Officer (Age 53)

When did Orphazyme A/S IPO?

(ORPH) raised $100 million in an initial public offering on Tuesday, September 29th 2020. The company issued 7,600,000 shares at $13.13 per share. BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO and Danske Markets was co-manager.

What is Orphazyme A/S's stock symbol?

Orphazyme A/S trades on the NASDAQ under the ticker symbol "ORPH."

When does the company's quiet period expire?

Orphazyme A/S's quiet period expires on Monday, November 9th. Orphazyme A/S had issued 7,616,146 shares in its IPO on September 29th. The total size of the offering was $83,777,606 based on an initial share price of $11.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Orphazyme A/S?

Shares of ORPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Orphazyme A/S's stock price today?

One share of ORPH stock can currently be purchased for approximately $9.27.

How big of a company is Orphazyme A/S?

Orphazyme A/S has a market capitalization of $321.31 million. Orphazyme A/S employs 114 workers across the globe.

What is Orphazyme A/S's official website?

The official website for Orphazyme A/S is www.orphazyme.com.

How can I contact Orphazyme A/S?

Orphazyme A/S's mailing address is OLE MAALOES VEJ 3, COPENHAGEN N G7, DK-2200. The company can be reached via phone at 45 39 17 82 72 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.